论文部分内容阅读
目的研究复方左旋多巴联合普拉克索治疗帕金森病的临床疗效及不良反应。方法 88例帕金森病患者,随机分为对照组和实验组,各44例。对照组给予复方左旋多巴治疗,实验组在对照组基础上加用普拉克索治疗。比较两组患者治疗前后统一帕金森病评定量表(UPDRS)评分和不良反应。结果治疗前,两组患者的UPDRSⅠ、UPDRSⅡ、UPDRSⅢ评分比较,差异均无统计学意义(P>0.05)。经4个月治疗后,两组患者的UPDRSⅠ、UPDRSⅡ、UPDRSⅢ评分均较本组治疗前降低,且治疗后实验组低于对照组,差异均具有统计学意义(P<0.05)。对照组不良反应发生率为18.2%,实验组不良反应发生率为15.9%,对比差异无统计学意义(P>0.05)。结论复方左旋多巴联合普拉克索治疗帕金森病疗效显著,较药物单用不良反应未见加重,值得临床借鉴。
Objective To study the clinical efficacy and adverse reactions of compound levodopa and pramipexole in the treatment of Parkinson’s disease. Methods 88 patients with Parkinson’s disease were randomly divided into control group and experimental group, 44 cases in each. The control group was treated with compound levodopa, and the experimental group was treated with pramipexole on the basis of the control group. The UPDRS scores and adverse reactions were compared between the two groups before and after treatment. Results Before treatment, UPDRS Ⅰ, UPDRS Ⅱ and UPDRS Ⅲ scores of two groups had no significant difference (P> 0.05). After 4 months of treatment, UPDRS Ⅰ, UPDRS Ⅱ and UPDRS Ⅲ scores of both groups were lower than those before treatment, and the experimental group was lower than the control group after treatment. The differences were statistically significant (P <0.05). The incidence of adverse reactions in the control group was 18.2%, and the incidence of adverse reactions in the experimental group was 15.9%. There was no significant difference between the two groups (P> 0.05). Conclusion Compound levodopa combined with pramipexole treatment of Parkinson’s disease has a significant effect, compared with drug-induced adverse reactions no increase, it is worth learning from.